Literature DB >> 24321371

Histone deacetylases in cardiac fibrosis: current perspectives for therapy.

Hui Tao1, Kai-Hu Shi2, Jing-Jing Yang3, Cheng Huang4, Hong-Ying Zhan1, Jun Li5.   

Abstract

Cardiac fibrosis is an important pathological feature of cardiac remodeling in heart diseases. The molecular mechanisms of cardiac fibrosis are unknown. Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In recent years, the role of HDACs in cardiac fibrosis initiation and progression, as well as the therapeutic effects of HDAC inhibitors, has been well studied. Moreover, numerous studies indicated that HDAC activity is associated with the development and progression of cardiac fibrosis. In this review, the innovative aspects of HDACs are discussed, with respect to biogenesis, their role in cardiac fibrosis. Furthermore, the potential applications of HDAC inhibitors in the treatment of cardiac fibrosis associated with fibroblast activation and proliferation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac fibrosis; ECM; Epigenetic; Extracellular matrix; FGF; Fibroblast; Fibroblast growth factor; HATs; HDACs; Histone acetyltransferases; Histone deacetylase; Histone deacetylases; Histone deacetylation; IGF-II/mannose 6-phosphate receptor; IGF-IIR/Man-6-P; MEF2; Myocyte enhancer factor-2; NRVMs; Neonatal rat ventricular myocytes; PDGF; PKD1; Platelet-derived growth factor; Proliferation; Protein kinase D1; TGF-β1; TIMPs; Tissue inhibitors of matrix metalloproteinases; Transforming growth factor β1; α-SMA; α-smooth muscle actin

Mesh:

Substances:

Year:  2013        PMID: 24321371     DOI: 10.1016/j.cellsig.2013.11.037

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  16 in total

Review 1.  Clinical applications of epigenetics in cardiovascular disease: the long road ahead.

Authors:  Stella Aslibekyan; Steven A Claas; Donna K Arnett
Journal:  Transl Res       Date:  2014-04-08       Impact factor: 7.012

2.  Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.

Authors:  Young Mi Seok; Hae Ahm Lee; Kwon Moo Park; Mi-Hyang Hwangbo; In Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-22       Impact factor: 3.000

3.  Deletion of protein kinase D1 in osteoprogenitor cells results in decreased osteogenesis in vitro and reduced bone mineral density in vivo.

Authors:  Wendy B Bollag; Vivek Choudhary; Qing Zhong; Ke-Hong Ding; Jianrui Xu; Ranya Elsayed; Kanglun Yu; Yun Su; Lakiea J Bailey; Xing-Ming Shi; Mohammed Elsalanty; Maribeth H Johnson; Meghan E McGee-Lawrence; Carlos M Isales
Journal:  Mol Cell Endocrinol       Date:  2017-08-12       Impact factor: 4.102

Review 4.  Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead.

Authors:  Hui Tao; Jing-Jing Yang; Wei Hu; Kai-Hu Shi; Zi-Yu Deng; Jun Li
Journal:  Pflugers Arch       Date:  2016-01-20       Impact factor: 3.657

Review 5.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

Review 6.  Epigenetic mechanisms in heart development and disease.

Authors:  Shannalee R Martinez; Maresha S Gay; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-01-06       Impact factor: 7.851

7.  Epigenetic factors MeCP2 and HDAC6 control α-tubulin acetylation in cardiac fibroblast proliferation and fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Inflamm Res       Date:  2016-03-14       Impact factor: 4.575

Review 8.  Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease.

Authors:  Zi-Ying Wang; Wen Qin; Fan Yi
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

9.  Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.

Authors:  Ajay Sharma; Nishant R Sinha; Saad Siddiqui; Rajiv R Mohan
Journal:  Mol Vis       Date:  2015-08-28       Impact factor: 2.367

10.  Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery.

Authors:  Ajay Sharma; Govindaraj Anumanthan; Marcos Reyes; Huiyi Chen; Jacob W Brubaker; Saad Siddiqui; Suneel Gupta; Frank G Rieger; Rajiv R Mohan
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-06-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.